Parkinson’s Disease | Disease Landscape & Forecast | G7 | 2025
Several new brands have recently entered the competitive Parkinson’s disease (PD) therapy market, including AbbVie’s Vyalev / Produodopa / Scyova (foslevodopa / foscarbidopa subcutaneous pump), Amneal’s Crexont (levodopa / carbidopa ER), and Supernus’s Onapgo (apomorphine subcutaneous pump), and several more are poised to launch within three years (e.g., Mitsubishi Tanabe / NeuroDerm’s ND0612, AbbVie’s tavapadon). Although clinical and commercial opportunity persists in PD, the market has proven challenging for some new entrants. As developers seek to establish a niche for their products, the treatment algorithm will become more complex. While new brands can drive market value, intense competition and patient and payer cost sensitivity in a generic drug market make for a challenging launch environment. With generic alternatives available in all PD drug classes, new brands that lack clinical differentiation will have difficulty competing. Meanwhile, potentially disruptive disease-modifying therapies (DMTs) are filling in the PD pipeline. A thorough grasp of current and future PD market dynamics is crucial for both new and established players vying for a share of this increasingly competitive landscape.
Questions answered:
- What will be the clinical and commercial impact of newly launched and emerging levodopa reformulations (i.e., Vyalev / Produodopa / Scyova, ND0612, and Crexont)?
- Where will AbbVie’s dopamine receptor agonist tavapadon fit into the treatment algorithm for PD?
- How do neurologists view the clinical prospects for adjunctive therapies for motor fluctuations, dyskinesia, and dementia?
- Which putative DMTs are most promising?
- Which unmet needs remain for other novel therapies targeting motor symptoms in PD?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Country-specific interviews with thought-leading neurologists; survey data collected for this and other Clarivate research
Epidemiology: Diagnosed and drug-treated prevalent cases of PD by country.
Drug treatments: Coverage of key current and late-phase emerging therapies
Forecast: 10-year, annualized, drug-level sales and patient share of key PD therapies through 2034, segmented by brands / generics and epidemiological subpopulations
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
